Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Navicare Biotech CoROCO:8472 -3.07%53 Days Payable is 301.00 as of Dec. 2025, which is 92% below its 10-year median of 3,861.12. GuruFocus rates ROCO:8472 with a GF Score™ of 53/100 and a GF Value™ of NT$44.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,099 Retail - Cyclical companies, Navicare Biotech Co ranks better than 94.9% on this metric.
The historical rank and industry rank for Navicare Biotech Co's Days Payable or its related term are showing as below:
ROCO:8472'
s Days Payable Range Over the Past 10 Years
Min: 294.89 Med: 3861.12 Max: 4949.48
Current: 294.89
During the past 13 years, Navicare Biotech Co's highest Days Payable was 4949.48. The lowest was 294.89. And the median was 3861.12.
ROCO:8472's Days Payable is ranked better than 94.9% of 1099
companies
in the Retail - Cyclical industry
Industry Median: 51.53
vs ROCO:8472: 294.89
Navicare Biotech Co's Days Payable
declined
from Dec. 2024 (554.46) to Dec. 2025 (301.00).
It may suggest that Navicare Biotech Coaccelerated paying its suppliers.
Navicare Biotech Co Days Payable Related Terms
Navicare Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: Days Payable Comparison
For the Internet Retail subindustry, Navicare Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co Days Payable vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Navicare Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a Days Payable of 301.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Navicare Biotech Co and its competitors. This is 92% below median its historical median of 3,861.12. Over the past decade, Navicare Biotech Co's Days Payable has ranged from 294.89 to 4,949.48. According to the industry distribution chart, Navicare Biotech Co ranks #56 out of 1099 companies in the Retail - Cyclical industry, placing it in the top 5.1%.
Is Navicare Biotech Co's Days Payable too high?
Navicare Biotech Co's current Days Payable of 301.00 is 92% below median its 10-year median of 3,861.12. Over the past 10 years, this metric has ranged from a low of 294.89 to a high of 4,949.48. The Retail - Cyclical industry median Days Payable is 51.53. Navicare Biotech Co's value of 301.00 is 484.1% above this industry median. Based on the distribution chart, Navicare Biotech Co ranks #56 out of 1099 companies in the Retail - Cyclical industry, which is in the top quartile — a strong position relative to peers. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's Days Payable compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #56 out of 1099 companies for Days Payable. This places Navicare Biotech Co in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 51.53. Navicare Biotech Co's value of 301.00 is 484.1% above this benchmark. Historically, Navicare Biotech Co's own Days Payable has ranged from 294.89 to 4,949.48 over the past decade. While the company's 10-year median is 3,861.12 vs. the industry median of 51.53, Navicare Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Retail - Cyclical company?
The median Days Payable among Retail - Cyclical companies is 51.53, based on 1,099 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navicare Biotech Co's current Days Payable of 301.00 is 484.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Navicare Biotech Co and its competitors. For the Retail - Cyclical industry, the median Days Payable is 51.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current Days Payable is 301.00, which is 92% below median its own 10-year median of 3,861.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current Days Payable is 301.00, which is 92% below median its 10-year median of 3,861.12 and 484.1% above the Retail - Cyclical industry median of 51.53. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current Days Payable is 301.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
Days Payable: 301.00 (92% below median its 10-year median of 3,861.12)
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
Industry Position: 484.1% above the Retail - Cyclical median (#56 of 1099)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
